Augustine Therapeutics is a biotechnology company focused on developing first-in-class therapies for rare neuromuscular and neurodegenerative diseases. Founded in 2019 as a spin-off from VIB and KU Leuven, the company's research is centered on the neuroprotective potential of small-molecule HDAC6 inhibitors, targeting diseases like Charcot-Marie-Tooth (CMT) and potentially Amyotrophic Lateral Sclerosis (ALS).

Augustine Therapeutics

Augustine Therapeutics focuses on the discovery and development of innovative medicines to benefit patients suffering from Charcot-Marie-Tooth disease (CMT), peripheral neuropathies and neurodegenerative disorders. The  company is rooted in the ground-breaking research at VIB and KU Leuven and supported by V-Bio Ventures, PMV, AdBio Partners, VIB New Ventures and Gemma Frisius Fund.  

——— *Disclaimer* ——— 
We wish to caution jobseekers that Augustine Therapeutics, only recruits for the positions that are posted on the company’s webpage and via the channels mentioned there. It will also not charge fees of any kind from candidates during the recruitment process. Any person or organization dealing with unauthorized parties is doing so at their own risk.

AdBio partners

V-Bio Ventures

Gemma Frisius Fund

Augustine Therapeutics will be participating to the BIO-EUROPE conference in Munich, Germany on 6-8 November 2023.

Sylvain Celanire, CEO will be available for one-on-one meetings throughout the 3-day conference.

To schedule a meeting, please reach out to us via: https://lnkd.in/gRkjn8M

We will be sharing the latest development on our small molecule HDAC6 inhibitor projects portfolio, including our peripheral-restricted clinical candidate AGT100216 advancing into regulatory development for Charcot-Marie-Tooth disease and Chemotherapy-induced neuropathies, as well as our brain penetrant selective HDAC6 inhibitor program for neurodegenerative diseases, including ALS.

➡ Agenda of Bio-Europe: https://lnkd.in/eXzpc2S2

#lifesciences #bioeurope #biopharma #CIPN  #CMT #ALS #innovation

Meet our new members at Augustine Therapeutics!

We are pleased to announce new appointments to our Leadership team to support the preclinical and clinical development of our peripheral-restricted and centrally acting selective HDAC6 inhibitor pipeline!

Marie Trad joins us as our Chief Medical Officer with extensive experience in clinical and pharmaceutical development in the field of neurology, neuromuscular, and neuropathies, leading global clinical development from early stages throughout the lifecycle of Augustine’s assets development. 

Jonathan van Eyll joins as our Head of Pharmacology. His large experience spanning from in vitro and in vivo translational pharmacology to clinical disease biomarkers of neuroscience therapeutics will strengthen our expertise in accelerating the discovery and development of selective HDAC6 inhibitors for neuromuscular and neurological diseases.

Finally, Cedric Szyndralewiez joins us as Head of Non-Clinical and Early Development, with a strong track record in leading and advancing multiple drug candidates through all stages of preclinical, IND approval to First-in-Patient studies.

We are also expanding our discovery and development platform by joining the Leuven-based Arenberg Accelerator, accessing state-of-the-art laboratories and offices! 

Exciting times for Augustine Therapeutics thanks to the continuous support of our historical investors V-Bio Ventures, PMV, AdBio partners, #VIBNewVentures, VIB, and GEMMA FRISIUS - FONDS K.U.LEUVEN!

To learn more about our exciting new team members, read the full Press Release here: https://lnkd.in/eabJnxNM

#newappointment #biotech #team #healthcare #innovation #pharma #drugdevelopment 

Augustine Therapeutics is proud to sponsor the 2023 Global CMT Research Convention, organized by the US CMT Research Foundation, to be held on September 22nd & 23rd at the Royal Sonesta Boston, Cambridge, MA.

The event is gathering researchers, biotech and pharma companies, investors, and patients to discuss widely the latest research and development towards finding a cure for Charcot-Marie-Tooth patients. This yearly convention enhances the scope and possibilities of research discoveries as a step forward for the people who are living with CMT!

Our CEO, Dr. Sylvain Celanire, will participate as a panel speaker during both Scientific and Patient Community Days:

·       Pushing boundaries in CMT research of early biotech companies – Friday, Sept 22nd afternoon.
 
·       Patient-Powered Perspectives: Biotech Insights on CMT and Collaborating with Patients – Saturday, Sept 23rd afternoon.

We feel extremely thankful to CMT Research Foundation for providing such a global platform. This boosts awareness amongst every individual going through CMT and helps us work with that objective.

Augustine Therapeutics is currently advancing AGT100216 clinical candidate toward a First-in-man clinical trial. AGT100216 is a highly selective, orally bioavailable, and safe HDAC6 inhibitor belonging to a unique and unprecedented chemical class. We have recently communicated at the 2023 PNS conference held in Copenhagen the outstanding preclinical efficacy of AGT100216, not only halting CMT1A disease progression but also significantly reversing disease phenotype and rescuing axonal integrity in a dose-dependent manner after only 4 weeks of low dose oral daily treatment.

Find out details of the event and agenda here: https://lnkd.in/e4uEpnDy

#raredisease #drugdevelopment #healthcareinnovation #research #charcotmarietooth #CMTRF #CMTresearch #CMTconvention

COM:AUGUSTINETX

Augustine Therapeutics

Financials Not Available